Zonisamide for prevention of Atypical (Second generation) antipsychotics associated weight gain in schizophrenia

Zonisamide for prevention of Atypical (Second generation) antipsychotics associated weight gain in schizophrenia : A double- blind, placebo controlled trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201103283930N5

Enrollment

Registered

2011-07-13

Start date

2011-03-28

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia. Schizophrenia

Interventions

Intervention 1: Zonisamide (150mg/day), Single dosage. Intervention 2: Placeb.

Treatment - Drugs

Placebo

Zonisamide (150mg/day), Single dosage

Placeb

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria are: age range of 16 to 65; lack of any reported neurological disease; lack of reported thyroid function problem; lack of current active substance use; lack of taking medication leading to significant weight gain or loss; no taking sulfanomides; lack of self reported kidney stone. Exclusion criteria are: lack of providing written consent; any serious medical condition such as epilepsy, thyroid function problems, diabetes; breast feeding; pregnancy; any special nutritional regime or intensive exercise program to decease weight.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hight. Timepoint: preintervention, weeks of 4, 8, and 10. Method of measurement: centimeter.;Weight. Timepoint: preintervention, weeks of 4, 8, and 10. Method of measurement: kilogram.;Waist circumference. Timepoint: preintervention, weeks of 4, 8, and 10. Method of measurement: Centimeter.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026